JP2020533336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533336A5 JP2020533336A5 JP2020514270A JP2020514270A JP2020533336A5 JP 2020533336 A5 JP2020533336 A5 JP 2020533336A5 JP 2020514270 A JP2020514270 A JP 2020514270A JP 2020514270 A JP2020514270 A JP 2020514270A JP 2020533336 A5 JP2020533336 A5 JP 2020533336A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- rtx
- group
- preparation
- alcoholic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 16
- 230000001476 alcoholic effect Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
- 229940043349 potassium metabisulfite Drugs 0.000 description 2
- 235000010263 potassium metabisulphite Nutrition 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- VIMFRQPQNUFOEQ-UHFFFAOYSA-M sodium;hydrogen sulfate;propan-2-one Chemical compound [Na+].CC(C)=O.OS([O-])(=O)=O VIMFRQPQNUFOEQ-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162509A JP2022176377A (ja) | 2017-09-11 | 2022-10-07 | レシニフェラトキシンの製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556824P | 2017-09-11 | 2017-09-11 | |
| US62/556,824 | 2017-09-11 | ||
| PCT/IB2018/056944 WO2019049112A1 (en) | 2017-09-11 | 2018-09-11 | RESINIFERATOXIN FORMULATION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162509A Division JP2022176377A (ja) | 2017-09-11 | 2022-10-07 | レシニフェラトキシンの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533336A JP2020533336A (ja) | 2020-11-19 |
| JP2020533336A5 true JP2020533336A5 (cg-RX-API-DMAC7.html) | 2021-10-21 |
| JP7358337B2 JP7358337B2 (ja) | 2023-10-10 |
Family
ID=63708422
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514270A Active JP7358337B2 (ja) | 2017-09-11 | 2018-09-11 | レシニフェラトキシンの製剤 |
| JP2022162509A Pending JP2022176377A (ja) | 2017-09-11 | 2022-10-07 | レシニフェラトキシンの製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162509A Pending JP2022176377A (ja) | 2017-09-11 | 2022-10-07 | レシニフェラトキシンの製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190076396A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3681472A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7358337B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200051771A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111315360B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018327301B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3074951A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020002692A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019049112A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11447444B1 (en) | 2019-01-18 | 2022-09-20 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| US11254659B1 (en) | 2019-01-18 | 2022-02-22 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| WO2020226370A1 (ko) | 2019-05-09 | 2020-11-12 | 주식회사 엘지화학 | 전기화학소자용 분리막 및 이를 포함하는 전기화학소자 |
| US20230143545A1 (en) * | 2020-03-30 | 2023-05-11 | Board Of Regents Of The University Of Nebraska | Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering Resiniferatoxin |
| ES3004508T3 (en) * | 2020-04-15 | 2025-03-12 | Gruenenthal Gmbh | Resiniferatoxin compositions |
| WO2021257956A1 (en) * | 2020-06-19 | 2021-12-23 | Sorrento Therapeutics, Inc. | Administration of resiniferatoxin for treatment of bladder pain or bladder cancer |
| EP4291174A1 (en) * | 2021-02-11 | 2023-12-20 | Sorrento Therapeutics, Inc. | Administration of resiniferatoxin for treatment of prostate cancer |
| US20250228765A1 (en) | 2024-01-15 | 2025-07-17 | Gruenenthal Gmbh | Treating knee joint pain by injecting resiniferatoxin at ultra low doses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2187193B (en) | 1986-02-27 | 1989-11-08 | Gerald Scott | Controllably and swiftly degradable polymer compositions and films and other products made therefrom |
| US5021450A (en) | 1989-05-30 | 1991-06-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof |
| US5232684A (en) | 1990-06-29 | 1993-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Labelled resiniferatoxin, compositions thereof, and methods for using the same |
| US20040146590A1 (en) | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
| NZ540769A (en) * | 2002-12-18 | 2009-03-31 | Algorx Pharmaceuticals Inc | Administration of capsaicinoids for the treatment of pain |
| CN101119713A (zh) * | 2004-11-24 | 2008-02-06 | 阿尔高克斯制药公司 | 类辣椒素凝胶制剂及其用途 |
| EP1838301B1 (de) * | 2004-12-28 | 2015-01-28 | Mestex AG | Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen |
| ES2384244T3 (es) * | 2004-12-28 | 2012-07-02 | Mestex Ag | Utilización de un agonista del receptor vaniloide juntamente con un glicosaminoglicano o un proteoglicano para la fabricación de un fármaco para el tratamiento de los dolores articulares y procedimiento para la aplicación de este fármaco |
| US9956166B2 (en) * | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
| CN113490745A (zh) * | 2018-12-21 | 2021-10-08 | 索伦托药业有限公司 | 神经周施用树脂毒素治疗适应不良性疼痛 |
| WO2020154261A1 (en) * | 2019-01-22 | 2020-07-30 | Sorrento Therapeutics, Inc. | Method for treating osteoarthritis pain by administering resiniferatoxin |
-
2018
- 2018-09-11 US US16/128,053 patent/US20190076396A1/en not_active Abandoned
- 2018-09-11 EP EP18779459.9A patent/EP3681472A1/en not_active Withdrawn
- 2018-09-11 CA CA3074951A patent/CA3074951A1/en active Pending
- 2018-09-11 MX MX2020002692A patent/MX2020002692A/es unknown
- 2018-09-11 AU AU2018327301A patent/AU2018327301B2/en not_active Ceased
- 2018-09-11 WO PCT/IB2018/056944 patent/WO2019049112A1/en not_active Ceased
- 2018-09-11 CN CN201880072756.3A patent/CN111315360B/zh active Active
- 2018-09-11 JP JP2020514270A patent/JP7358337B2/ja active Active
- 2018-09-11 KR KR1020207010367A patent/KR20200051771A/ko not_active Ceased
-
2020
- 2020-03-10 MX MX2022013947A patent/MX2022013947A/es unknown
-
2022
- 2022-01-05 US US17/569,340 patent/US20220370405A1/en not_active Abandoned
- 2022-10-07 JP JP2022162509A patent/JP2022176377A/ja active Pending
-
2024
- 2024-03-29 US US18/622,139 patent/US20250000842A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arabi et al. | Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial | |
| RU2607892C2 (ru) | Композиции на основе ксилита, препятствующие отделению слизи, а также смежные способы и композиции | |
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| JP2014139229A5 (cg-RX-API-DMAC7.html) | ||
| JP2012505172A5 (cg-RX-API-DMAC7.html) | ||
| JOP20250145A1 (ar) | صيغ لتركيبات لقاح فيروس حُمى الضنك | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| CO6640268A2 (es) | Formas de decodificación oral de bendamustina y su uso terapéutico | |
| JP2014530801A5 (cg-RX-API-DMAC7.html) | ||
| MX2022012359A (es) | Formulacion. | |
| PE20080422A1 (es) | Composicion solida antirretroviral de administracion oral | |
| MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| ZA201908610B (en) | Il-15 protein complex pharmaceutical composition and uses thereof | |
| JP7358337B2 (ja) | レシニフェラトキシンの製剤 | |
| Lin et al. | Viral infection induces inflammatory signals that coordinate YAP regulation of dysplastic cells in lung alveoli | |
| JP2022511335A5 (cg-RX-API-DMAC7.html) | ||
| HRP20160286T1 (hr) | Tekuća farmaceutska kompozicija koja sadrži nitizinon | |
| PH12021551226A1 (en) | Monomethyl fumarate-carrier conjugates and methods of their use | |
| MX2022000267A (es) | Composiciones comprimidas de macitentan, metodos y usos de las mismas. | |
| ES2239802T3 (es) | Composiciones farmaceuticas. | |
| FI3554474T3 (fi) | Mikafungiinikoostumuksia | |
| JP2016534062A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0508798A (pt) | formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento | |
| WO2020053658A3 (en) | Non-aqueous chemotherapeutic solutions for oral dosage | |
| AR062674A1 (es) | Formulacion acuosa que comprende un agente antitumoral |